JASPER THERAPEUTICS INC (JSPR) Stock Price, Quote, News and Overview
NASDAQ:JSPR - Nasdaq - US4718712023 - Common Stock - Currency: USD
JSPR Quote, Performance and Key Statistics
4.32
-0.42 (-8.86%)
The current stock price of JSPR is 4.32 USD. In the past month the price increased by 24.5%. In the past year, price decreased by -79.75%.
JSPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.73B | ||
| AMGN | AMGEN INC | 13.29 | 148.31B | ||
| GILD | GILEAD SCIENCES INC | 12.78 | 123.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 60.56B | ||
| ARGX | ARGENX SE - ADR | 327.86 | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 25.03B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.31B | ||
| NTRA | NATERA INC | N/A | 21.77B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.04B | ||
| BIIB | BIOGEN INC | 7.41 | 17.17B |
Related stock screener links
About JSPR
Company Profile
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 64 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). The company also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Company Info
JASPER THERAPEUTICS INC
2200 Bridge Pkwy Suite #102
Redwood City CALIFORNIA US
CEO: Bala Venkataraman
Employees: 64
Phone: 16505491400
JASPER THERAPEUTICS INC / JSPR FAQ
What is the stock price of JASPER THERAPEUTICS INC today?
The current stock price of JSPR is 4.32 USD. The price decreased by -8.86% in the last trading session.
What is the ticker symbol for JASPER THERAPEUTICS INC stock?
The exchange symbol of JASPER THERAPEUTICS INC is JSPR and it is listed on the Nasdaq exchange.
On which exchange is JSPR stock listed?
JSPR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for JASPER THERAPEUTICS INC stock?
17 analysts have analysed JSPR and the average price target is 57.76 USD. This implies a price increase of 1236.98% is expected in the next year compared to the current price of 4.32. Check the JASPER THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is JASPER THERAPEUTICS INC worth?
JASPER THERAPEUTICS INC (JSPR) has a market capitalization of 64.89M USD. This makes JSPR a Micro Cap stock.
How many employees does JASPER THERAPEUTICS INC have?
JASPER THERAPEUTICS INC (JSPR) currently has 64 employees.
What are the support and resistance levels for JASPER THERAPEUTICS INC (JSPR) stock?
JASPER THERAPEUTICS INC (JSPR) has a resistance level at 5.37. Check the full technical report for a detailed analysis of JSPR support and resistance levels.
Should I buy JASPER THERAPEUTICS INC (JSPR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of JSPR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of JSPR, evaluating the profitability, health, valuation and growth aspects
- JASPER THERAPEUTICS INC (JSPR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- JASPER THERAPEUTICS INC (JSPR) Sales and EPS estimates to see what analysts future expectations are.
- JASPER THERAPEUTICS INC (JSPR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- JASPER THERAPEUTICS INC (JSPR) Insider and Institutional Ownership to learn about the owners and their transactions.
- JASPER THERAPEUTICS INC (JSPR) Stock Chart to make your own analysis
- JASPER THERAPEUTICS INC (JSPR) Latest news and press-releases to stay up to date.
Does JASPER THERAPEUTICS INC (JSPR) stock pay dividends?
JSPR does not pay a dividend.
When does JASPER THERAPEUTICS INC (JSPR) report earnings?
JASPER THERAPEUTICS INC (JSPR) will report earnings on 2025-05-12, after the market close.
What is the Price/Earnings (PE) ratio of JASPER THERAPEUTICS INC (JSPR)?
JASPER THERAPEUTICS INC (JSPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.86).
What is the Short Interest ratio of JASPER THERAPEUTICS INC (JSPR) stock?
The outstanding short interest for JASPER THERAPEUTICS INC (JSPR) is 12.06% of its float. Check the ownership tab for more information on the JSPR short interest.
JSPR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to JSPR. When comparing the yearly performance of all stocks, JSPR is a bad performer in the overall market: 94.77% of all stocks are doing better.
JSPR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JSPR. While JSPR seems to be doing ok healthwise, there are quite some concerns on its profitability.
JSPR Financial Highlights
Over the last trailing twelve months JSPR reported a non-GAAP Earnings per Share(EPS) of -4.86. The EPS increased by 21.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.2% | ||
| ROE | -115.56% | ||
| Debt/Equity | 0 |
JSPR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to JSPR. The Buy consensus is the average rating of analysts ratings from 17 analysts.